Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:AVDL NASDAQ:GTHX NASDAQ:PGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$29.42+0.8%$25.21$20.39▼$53.96$1.37B0.8609,510 shs414,943 shsAVDLAvadel Pharmaceuticals$15.76+5.1%$12.00$6.38▼$16.66$1.53B1.581.28 million shs2.02 million shsGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/APGENPrecigen$4.36-4.4%$2.48$0.65▼$5.22$1.30B1.8217.94 million shs6.25 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+0.79%-3.92%+41.31%+13.20%-37.27%AVDLAvadel Pharmaceuticals+5.14%+6.78%+41.98%+62.14%+7.07%GTHXG1 Therapeutics0.00%0.00%0.00%0.00%+0.28%PGENPrecigen-4.39%-3.33%+138.25%+190.67%+351.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$29.42+0.8%$25.21$20.39▼$53.96$1.37B0.8609,510 shs414,943 shsAVDLAvadel Pharmaceuticals$15.76+5.1%$12.00$6.38▼$16.66$1.53B1.581.28 million shs2.02 million shsGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/APGENPrecigen$4.36-4.4%$2.48$0.65▼$5.22$1.30B1.8217.94 million shs6.25 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+0.79%-3.92%+41.31%+13.20%-37.27%AVDLAvadel Pharmaceuticals+5.14%+6.78%+41.98%+62.14%+7.07%GTHXG1 Therapeutics0.00%0.00%0.00%0.00%+0.28%PGENPrecigen-4.39%-3.33%+138.25%+190.67%+351.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.40Hold$31.607.41% UpsideAVDLAvadel Pharmaceuticals 3.11Buy$20.8632.34% UpsideGTHXG1 Therapeutics 0.00N/AN/AN/APGENPrecigen 2.80Moderate Buy$8.2589.22% UpsideCurrent Analyst Ratings BreakdownLatest GTHX, AVDL, AMPH, and PGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $36.009/3/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/3/2025AVDLAvadel PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$16.008/26/2025AMPHAmphastar PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$28.00 ➝ $32.008/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.008/19/2025PGENPrecigenCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/19/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$6.00 ➝ $8.008/19/2025PGENPrecigenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.508/15/2025PGENPrecigenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral8/13/2025PGENPrecigenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$722.68M1.89$5.05 per share5.83$15.23 per share1.93AVDLAvadel Pharmaceuticals$221.08M6.92N/AN/A$0.77 per share20.47GTHXG1 Therapeutics$58.20M6.42N/AN/A$0.68 per share10.51PGENPrecigen$4.34M299.35N/AN/A$0.13 per share33.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$159.52M$2.6711.028.94N/A18.64%20.76%9.68%11/5/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A262.67N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)GTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/APGENPrecigen-$126.24M-$0.42N/AN/AN/A-2,868.66%-842.83%-78.98%11/13/2025 (Estimated)Latest GTHX, AVDL, AMPH, and PGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PGENPrecigen-$0.14-$0.11+$0.03-$0.09$0.67 million$0.86 million8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.803.292.21AVDLAvadel PharmaceuticalsN/A2.792.38GTHXG1 Therapeutics1.342.482.12PGENPrecigenN/A2.712.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%AVDLAvadel Pharmaceuticals69.19%GTHXG1 Therapeutics24.21%PGENPrecigen33.51%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.50%AVDLAvadel Pharmaceuticals5.20%GTHXG1 Therapeutics6.11%PGENPrecigen47.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals2,02846.50 million33.71 millionOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableGTHXG1 Therapeutics17052.28 million49.09 millionOptionablePGENPrecigen190297.97 million157.63 millionOptionableGTHX, AVDL, AMPH, and PGEN HeadlinesRecent News About These CompaniesPrecigen (NASDAQ:PGEN) Director Acquires $69,000.00 in StockSeptember 6 at 8:29 AM | insidertrades.comPrecigen (NASDAQ:PGEN) Sets New 1-Year High - Here's What HappenedSeptember 5 at 4:55 AM | marketbeat.comPrecigen (NASDAQ:PGEN) Trading Up 7.8% - Here's What HappenedSeptember 4 at 1:47 PM | marketbeat.comPrecigen Secures $125M Loan for PAPZIMEOS ExpansionSeptember 3 at 7:31 AM | tipranks.comPrecigen Announces Up to $125 Million Non-Dilutive FinancingSeptember 3 at 7:00 AM | prnewswire.comPrecigen, Inc. - Special CallSeptember 2, 2025 | seekingalpha.comPrecigen, Inc. (PGEN) H.C. Wainwright Virtual Fireside Chat TranscriptSeptember 2, 2025 | seekingalpha.comCharles Schwab Investment Management Inc. Sells 62,098 Shares of Precigen, Inc. $PGENSeptember 2, 2025 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN)September 2, 2025 | finance.yahoo.comPrecigen (NASDAQ:PGEN) & Pathfinder Cell Therapy (OTCMKTS:PFND) Head to Head SurveySeptember 1, 2025 | americanbankingnews.comNancy Agee Buys 15,360 Shares of Precigen (NASDAQ:PGEN) StockAugust 30, 2025 | insidertrades.comPrecigen (NASDAQ:PGEN) Hits New 12-Month High - Here's WhyAugust 29, 2025 | marketbeat.comPrecigen (PGEN) Is Up 32.3% After FDA Approval of First Therapy for Recurrent Respiratory PapillomatosisAugust 27, 2025 | finance.yahoo.comCitizens JMP Raises PT on Precigen from $6 to $8, Keeps Outperform RatingAugust 26, 2025 | insidermonkey.comH.C. Wainwright Remains Bullish on Precigen (PGEN)August 26, 2025 | finance.yahoo.comPGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease DrugAugust 25, 2025 | zacks.comPrecigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. WainwrightAugust 25, 2025 | prnewswire.comPrecigen Inc. (PGEN) Stock Price Today - WSJAugust 22, 2025 | wsj.comCantor Fitzgerald Cuts Earnings Estimates for PrecigenAugust 22, 2025 | marketbeat.comPrecigen (NASDAQ:PGEN) Trading Up 10.9% After Analyst UpgradeAugust 21, 2025 | marketbeat.comPrecigen, Inc. (NASDAQ:PGEN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGTHX, AVDL, AMPH, and PGEN Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$29.42 +0.23 (+0.79%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$29.44 +0.01 (+0.05%) As of 09/5/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Avadel Pharmaceuticals NASDAQ:AVDL$15.76 +0.77 (+5.14%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$15.82 +0.06 (+0.38%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.G1 Therapeutics NASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Precigen NASDAQ:PGEN$4.36 -0.20 (-4.39%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$4.34 -0.02 (-0.46%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
